Skip to main content

Table 1 Characteristics of study subjects

From: The rs361525 polymorphism does not increase production of tumor necrosis factor alpha by monocytes from alpha-1 antitrypsin deficient subjects with chronic obstructive pulmonary disease - a pilot study

Characteristic

rs361525 + ve (AG/AA)

rs361525 -ve (GG)

P value (2- tailed)

N

9

9

 

(8 AG/1 AA)

Presence of COPD

9/9

9/9

 

Age in years

51 (50–65)

60 (49–61)

0.8

Male

7 (77.8)

7 (77.8)

 

AATD level (micromolar)

3.8 (0.4)

4.0 (0.5)

0.8

BMI

21.2 (21.0–23.8)

23.2 (22.0–26.0)

0.3

Smoking hx

Current

1

0

 

Ex/never

7/1

8/1

 

Pack years

22 (10–28)

22 (9–30)

0.9

FEV1 (L)

1.4 (0.1)

1.4 (0.2)

0.8

FEV1 % predicted

37.7 (33.4–43.4)

33.6 (32.6–54.6)

0.9

FEV1/FVC ratio (%)

32.0 (28.0–34.0)

32.2 (23.0–33.0)

0.5

KCO % predicted

53.9 (4.6)

52.0 (4.8)

0.8

Emphysema on HRCT

8/9

9/9

 

Chronic bronchitis phenotype

4/9

5/9

 

Bronchiectasis on HRCT

4/9

5/9

 

Inhaled steroids

8/9

9/9

 

Median exacerbations per year

1.0 (1.0–2.0)

0.5 (0–1.0)

0.3

  1. The table shows key characteristics of subjects with (AG/AA) and without (GG) the rs361525 TNF-α polymorphism. Subjects were matched as closely as possible. Data is given as mean (SE) where normally distributed and median (IQR) where not normally distributed. An independent t-test was used to detect any difference between groups for the former data and a Mann Whitney U test for the latter